To Pretreat or Not to Pretreat (With Oral P2Y12 Antagonists)? That is the Question

J Am Heart Assoc. 2017 Sep 22;6(9):e007288. doi: 10.1161/JAHA.117.007288.

Authors

Angela Lowenstern¹, L Kristin Newby²

Affiliations

¹ Division of Cardiology, Department of Medicine and the Duke Clinical Research Institute, Duke University Medical Center, Durham, NC.
² Division of Cardiology, Department of Medicine and the Duke Clinical Research Institute, Duke University Medical Center, Durham, NC kristin.newby@duke.edu.

No abstract available

Keywords: Editorials; acute coronary syndrome; antiplatelet therapy; coronary artery bypass graft surgery.

Publication types

Editorial
Comment

MeSH terms

Cardiac Catheterization
Coronary Artery Bypass
Humans
Non-ST Elevated Myocardial Infarction*
Purinergic P2Y Receptor Antagonists
Registries

Substances

Purinergic P2Y Receptor Antagonists